ERAS Erasca, Inc.
ERAS Erasca, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $14.58 · VWAP $13.02 · +2.9% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
ERAS Price Structure
Loading timeframes…
Peers
Every watchlist ERAS belongs to, members best 30-day change first — ERAS highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: diluted EPS -$0.14, net income -$44M (SEC filing). Across the print the stock moved -2.5% (close before → first close after).
full note →Against street estimates
How ERAS's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about ERAS from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 24 days ago · Sep 23
- Erasca Q1 2026 results, cash runway into H2 2028 | ERAS Stock ...
- Erasca Reports Second Quarter 2026 Business Updates and Financial Results – Erasca
- Erasca: Investors
- Erasca Inc Stock Price Today | NASDAQ: ERAS Live - Investing.com
- Erasca Stock Price Today NASDAQ ERAS - Investing.com Canada
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
ERAS research tape
81 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.